Pegcetacoplan

What is Pegcetacoplan?

Pegcetacoplan is a symmetrical PEGylated cyclic peptide built on the compstatin scaffold — a 13-residue cyclic peptide originally discovered by phage display in John Lambris's laboratory that binds complement component C3 and blocks its cleavage to C3a and C3b. The marketed drug consists of two identical 15-amino-acid cyclic peptides (the 13-residue compstatin core plus a 2-residue linker) covalently coupled to each end of a linear 40 kDa polyethylene glycol (PEG) chain — yielding a bivalent C3 inhibitor with a plasma half-life of roughly 8 days, long enough to enable twice-weekly subcutaneous infusion (Empaveli) or every-25-to-60-day intravitreal injection (Syfovre). Pegcetacoplan was developed by Apellis Pharmaceuticals (Waltham, MA) and has received three FDA approvals: Empaveli for paroxysmal nocturnal hemoglobinuria (PNH, May 2021), Syfovre for geographic atrophy secondary to age-related macular degeneration (GA/AMD, February 2023), and Empaveli for C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) (July 2025) — the first-ever approved therapy for these rare kidney diseases. It is one of the largest commercial successes of the broader compstatin / complement-targeting peptide field and a defining example of a PEGylated peptide therapeutic.

What Pegcetacoplan Is Investigated For

Pegcetacoplan is one of the most clinically and commercially important peptide therapeutics of the last decade — an unambiguous proof point that PEGylated cyclic peptides can carry small-molecule-like target engagement into approved products across multiple specialties. Its three FDA approvals span hematology (PNH, 2021), ophthalmology (GA/AMD, 2023), and nephrology (C3G/IC-MPGN, July 2025), and each rests on a Phase 3 trial program: PEGASUS in PNH showed pegcetacoplan superior to eculizumab on hemoglobin response in patients still anemic on a C5 inhibitor; PRINCE confirmed efficacy in complement-inhibitor-naive PNH patients; OAKS and DERBY (combined Lancet 2023) demonstrated slowed lesion growth in GA over 24 months, with the GALE extension showing growth-rate reductions sustained out to 36–60 months; VALIANT was the first-ever positive Phase 3 in C3G/IC-MPGN, reporting roughly 68% proteinuria reduction at 26 weeks, eGFR stabilization, and clearance of C3 deposits on kidney biopsy. Mechanistically, pegcetacoplan is a proximal C3 inhibitor that blocks the complement cascade upstream of C5 — the level of intervention that distinguishes it from eculizumab and ravulizumab, and that allows it to address both intravascular and extravascular hemolysis in PNH (the C5-blocker-resistant component of PNH disease). The trade-offs are real: subcutaneous infusion twice weekly is more demanding than monthly C5 inhibitor injection, intravitreal Syfovre carries a small but meaningful risk of retinal vasculitis and intraocular inflammation, and proximal C3 blockade theoretically increases susceptibility to encapsulated-organism infections (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae) more than distal C5 blockade — meaning vaccination prior to therapy is mandatory and not optional.

History & Discovery

Pegcetacoplan's lineage runs back to the mid-1990s, when John Lambris's laboratory at the University of Pennsylvania ran phage-display screens against complement component C3 to identify cyclic peptide binders. The original lead — a 13-residue cyclic peptide called compstatin — bound C3 selectively and blocked its cleavage to C3a and C3b. The molecule was a useful biochemical probe but had a half-life and potency profile incompatible with clinical use. Over the next two decades, Lambris and colleagues iterated through analogs (4(1MeW), Cp40, POT-4) with progressively higher affinity and more drug-like properties, in collaboration with Daniel Ricklin and a growing community of complement-immunology investigators. The clinical translation arc began with Potentia Pharmaceuticals, an Alcon-spinout founded by Lambris and collaborators to advance compstatin analogs for ophthalmic indications. Potentia's POT-4 was an early intravitreal compstatin formulation investigated for AMD. The company was acquired and rebranded as Apellis Pharmaceuticals in 2009 by Cedric Francois (a Belgian transplant immunologist) and Pascal Deschatelets, who positioned Apellis around C3-pathway drug development across multiple specialties. The active drug substance was reformulated as a symmetrical bivalent PEGylated cyclic peptide — designated APL-2 internally and ultimately pegcetacoplan — to extend half-life into a clinically useful range. The Phase 3 program ran in parallel across three specialties. In paroxysmal nocturnal hemoglobinuria, the pivotal PEGASUS trial (Hillmen et al., NEJM 2021) randomized PNH patients still anemic on eculizumab to switch to pegcetacoplan or continue eculizumab, and pegcetacoplan was superior on hemoglobin change at 16 weeks; this was the registration-supporting study for the FDA approval of Empaveli in May 2021. The PRINCE trial extended efficacy to complement-inhibitor-naive PNH. In age-related macular degeneration, the OAKS and DERBY Phase 3 trials demonstrated slowed lesion growth in geographic atrophy over 12 and 24 months, with the GALE extension confirming sustained effect to 36–60 months; this supported the FDA approval of Syfovre in February 2023. In C3 glomerulopathy and immune-complex MPGN, the VALIANT Phase 3 trial reported ~68% proteinuria reduction, eGFR stabilization, and clearance of C3 deposits — the first-ever positive Phase 3 in this rare-disease space — leading to FDA approval of Empaveli for C3G/IC-MPGN in July 2025. Pegcetacoplan sits within a broader and increasingly crowded complement-therapeutics landscape. Adjacent peptide programs from Lambris's lineage include AMY-101 (Amyndas) and Cp40-related compstatin analogs in earlier-stage development. The terminal-complement antibody class (eculizumab, ravulizumab) remains the dominant alternative; oral factor B inhibitor iptacopan (Fabhalta, Novartis, 2023) and intravitreal complement factor D inhibitor izervay (avacincaptad pegol, Astellas, 2023) are direct competitors in PNH and GA respectively. The next several years will reshape positioning across all three indications, but pegcetacoplan's combination of three approved indications, multi-year long-term safety data, and a defined peptide-PEGylation drug-design template makes it a foundational molecule in the modern complement-targeting field.

How It Works

Pegcetacoplan is a small peptide ring (the active part of an older peptide called compstatin) hooked to both ends of a long flexible PEG chain. The peptide ring physically clamps onto complement C3 — a central immune-system protein — and prevents it from being cut into its active fragments. By blocking complement at C3, the drug shuts down both the destructive immune signals that drive paroxysmal nocturnal hemoglobinuria, the slow retinal damage of geographic atrophy in macular degeneration, and the kidney damage of C3 glomerulopathy. The PEG chain doesn't do anything pharmacologically itself — it just keeps the drug in circulation long enough to be useful.

Pegcetacoplan is a symmetrical PEGylated peptide built on the compstatin scaffold — a cyclic 13-residue peptide discovered by John Lambris and colleagues at the University of Pennsylvania in the mid-1990s by phage-display screening against complement component C3. The pegcetacoplan drug substance consists of two identical 15-amino-acid cyclic peptides (the 13-residue compstatin core extended by a 2-residue linker) covalently coupled to each end of a linear 40 kDa polyethylene glycol (PEG) chain. The bivalent design provides two C3-binding sites per molecule; the PEG chain extends the apparent molecular size to limit renal clearance and produces a plasma half-life of approximately 8 days in PNH patients, supporting twice-weekly subcutaneous infusion (Empaveli) or every-25-to-60-day intravitreal injection (Syfovre). Mechanistically, each cyclic peptide arm binds the C3 protein at a defined site (resolved by X-ray crystallography in the Lambris-laboratory compstatin structural series) and sterically blocks the C3 convertase enzyme from cleaving C3 to C3a and C3b. Because all three complement pathways — classical, lectin, and alternative — converge on C3 cleavage as the central amplification step, C3 inhibition silences essentially the entire downstream cascade: opsonization (C3b deposition on cell surfaces driving phagocytosis and extravascular hemolysis), anaphylatoxin generation (C3a and C5a driving inflammation and chemotaxis), and terminal complement complex assembly (C5b-9 driving intravascular hemolysis and direct cell lysis). This proximal blockade is the mechanistic distinction from terminal-complement inhibitors. Eculizumab and ravulizumab bind C5 and prevent assembly of the membrane attack complex — they stop intravascular hemolysis effectively but leave the C3b-mediated extravascular hemolysis arm intact, which is why a substantial fraction of PNH patients remain anemic and transfusion-dependent on C5 inhibitors. Pegcetacoplan addresses both arms by acting upstream of the divergence. The same logic applies in GA, where C3b deposition and alternative-pathway amplification drive RPE and photoreceptor loss, and in C3G/IC-MPGN, where alternative-pathway dysregulation drives glomerular C3 deposition. The trade-off of proximal C3 blockade is broader infection vulnerability — Neisseria, Streptococcus pneumoniae, and Haemophilus influenzae type b are more dependent on C3 opsonization than on terminal complement, so C3 inhibition carries a somewhat higher meningococcal and pneumococcal risk profile than C5 inhibition. This is the basis for the mandatory pre-therapy vaccination requirement across all pegcetacoplan indications.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Pegcetacoplan:

• 01Comparative effectiveness against next-generation complement therapeutics — head-to-head data versus oral factor B inhibitor iptacopan in PNH, versus intravitreal factor D inhibitor avacincaptad pegol (Izervay) in GA, and versus emerging C3-pathway competitors will reshape positioning across all three indications over the next several years.
• 02Long-term off-therapy remission in C3G/IC-MPGN — whether sustained pegcetacoplan suppression can produce durable remission allowing eventual treatment discontinuation is an open question; VALIANT extension data will inform this over multi-year follow-up.
• 03Pediatric and adolescent use beyond age 12 — the 2025 C3G/IC-MPGN approval is the broadest pediatric indication but younger-pediatric experience remains limited.
• 04Optimal vaccination schedule and durability — meningococcal serogroup-specific protection durability under chronic complement inhibition is incompletely characterized; revaccination intervals are based on extrapolation from C5-inhibitor experience.
• 05Real-world rates of meningococcal and pneumococcal infection on chronic pegcetacoplan — postmarketing pharmacovigilance is the main data source and is still maturing.
• 06Use during pregnancy — limited human exposure data exists; clarification of placental transfer, fetal complement effects, and long-term offspring follow-up is needed.
• 07Mechanism and management of Syfovre-associated retinal vasculitis and intraocular inflammation — incidence is low but the mechanism (immune-complex deposition? PEG-related? formulation-specific?) is not fully resolved.
• 08Adjacent indications — antiphospholipid syndrome, ANCA-associated vasculitis, hematopoietic stem cell transplant complications, kidney transplant antibody-mediated rejection, and other complement-driven conditions are areas of active investigation but not yet approved.

Forms & Administration

Empaveli (subcutaneous formulation): supplied as 1080 mg/20 mL pre-filled vials; standard adult dose is 1080 mg subcutaneously twice weekly via a small infusion pump over approximately 30 minutes, with two infusion sites used in parallel. Self-administered after training. Used for PNH (since 2021) and for C3G/IC-MPGN (since July 2025). Syfovre (intravitreal formulation): supplied in 100 mg/mL single-dose vials; standard dose is 15 mg (0.1 mL) intravitreal injection administered by a retina specialist every 25 to 60 days, with monthly dosing producing somewhat greater lesion-growth reduction than every-other-month dosing in OAKS/DERBY. Approved for geographic atrophy secondary to age-related macular degeneration (since February 2023). Both formulations require strict cold-chain storage and are distributed through specialty pharmacy networks under the Apellis Assist patient-support program in the US. All administration must be under the direction of a qualified clinician — there is no legitimate self-administered, off-label, wellness, or research-chemical channel for pegcetacoplan.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Pegcetacoplan is an FDA-approved prescription specialty drug for three defined indications (PNH, GA secondary to AMD, C3G/IC-MPGN). It is administered under the direction of a hematologist, retina specialist, or nephrologist depending on indication, with specialty-pharmacy distribution. There is no legitimate self-administered, off-label, wellness, or research-chemical use of pegcetacoplan, and any product marketed outside FDA-approved channels is not the authentic drug.

Timeline of Effects

Common Questions

Who Pegcetacoplan Is NOT For

Drug & Supplement Interactions

Pegcetacoplan is a peptide-PEG conjugate cleared by proteolysis and not by hepatic CYP-mediated metabolism, so classical small-molecule drug-interaction pathways are minimal. The clinically relevant interactions are pharmacodynamic. Switching between complement inhibitors: transitioning from eculizumab or ravulizumab (anti-C5 antibodies) to pegcetacoplan requires a defined overlap period — typically 4 weeks of dual therapy in PNH protocols — to prevent breakthrough hemolysis as the C5 inhibitor washes out. Conversely, switching from pegcetacoplan to a C5 inhibitor requires hematology supervision. Concurrent use of pegcetacoplan with other complement-pathway therapeutics (factor B inhibitor iptacopan, factor D inhibitors, future C3-pathway agents) is not a standard combination and would require individualized risk-benefit assessment. Live vaccines: live attenuated vaccines (varicella, zoster live, yellow fever, MMR, oral polio) should generally be avoided during pegcetacoplan therapy due to attenuated immune response to live organisms under complement suppression; inactivated vaccines (the meningococcal, pneumococcal, and Hib vaccines required pre-therapy; influenza; etc.) are safe but may have reduced immune response. Vaccination scheduling should be planned with the specialty-care team. Immunosuppressants and biologics: combination with chronic immunosuppression (post-transplant regimens, rituximab, anti-CD20 therapy, broad immunosuppressant cocktails) compounds infection risk; not contraindicated but requires intensified infection surveillance. Laboratory interference: pegcetacoplan does not interfere with classical clinical chemistry panels but can alter complement assays (CH50, AH50, C3, C4) — interpretation of complement labs in pegcetacoplan-treated patients should account for the on-drug pharmacodynamic state. As with any specialty medication, all prescription, OTC, and supplement use should be disclosed to the prescribing hematology, ophthalmology, or nephrology team.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions